Ossiam Reduces Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Ossiam decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 20.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,466 shares of the medical equipment provider’s stock after selling 3,718 shares during the quarter. Ossiam’s holdings in Zimmer Biomet were worth $1,761,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Naples Money Management LLC purchased a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $35,000. Activest Wealth Management grew its holdings in shares of Zimmer Biomet by 410.4% in the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 275 shares during the period. Blue Trust Inc. grew its holdings in shares of Zimmer Biomet by 48.4% in the fourth quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock valued at $52,000 after purchasing an additional 153 shares during the period. Quent Capital LLC lifted its position in Zimmer Biomet by 21.6% in the fourth quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock valued at $63,000 after buying an additional 92 shares during the last quarter. Finally, GAMMA Investing LLC purchased a new position in Zimmer Biomet during the fourth quarter worth about $65,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 0.4 %

Shares of Zimmer Biomet stock opened at $112.88 on Tuesday. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $147.50. The company has a 50 day moving average of $120.26 and a 200 day moving average of $122.06. The company has a quick ratio of 0.80, a current ratio of 1.66 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $23.22 billion, a P/E ratio of 24.43, a P/E/G ratio of 2.04 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBHGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.87 by $0.07. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The company had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter in the previous year, the firm earned $1.89 earnings per share. The firm’s quarterly revenue was up 3.2% on a year-over-year basis. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be issued a dividend of $0.24 per share. The ex-dividend date is Wednesday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.85%. Zimmer Biomet’s payout ratio is currently 20.78%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, May 30th. Barclays lowered their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating for the company in a research note on Friday, May 31st. Oppenheimer increased their target price on shares of Zimmer Biomet from $150.00 to $155.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Truist Financial lowered their target price on shares of Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating for the company in a research note on Friday, May 3rd. Finally, Argus raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 target price for the company in a research note on Tuesday, May 21st. One analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus price target of $133.75.

Get Our Latest Stock Report on Zimmer Biomet

Zimmer Biomet Company Profile

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Featured Stories

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.